Day-night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 913-918

  Barcelo, A ^a   Pierola J ^a   De La Pena M ^a   Esquinas, C ^b   Sanchez de La Torre, M ^a,b   Ayllon O ^a   Alonso, A ^a   Agusti, A G N ^a,c,d   Barbe, F ^a,b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Hospital Universitari Santa Maria Arnau de Vilanova   (Spain)

^c Hospital Universitari Santa Maria Arnau de Vilanova ^*  (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Endothelial; Sleep apnoea

Indexed keywords

BLOOD CLOTTING FACTOR 7; CD40 LIGAND; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; APNEA HYPOPNEA INDEX; AROUSAL; ARTICLE; BODY MASS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HEMOSTASIS; HUMAN; MALE; OBESITY; OXYGEN SATURATION; PATIENT ASSESSMENT; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; WAIST CIRCUMFERENCE;

ADULT; ARGININE; BLOOD COAGULATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CD40 LIGAND; CIRCADIAN RHYTHM; ENDOTHELIUM, VASCULAR; ERYTHROCYTE COUNT; FACTOR VII; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET COUNT; SLEEP APNEA SYNDROMES; VON WILLEBRAND FACTOR; WAIST CIRCUMFERENCE;

EID: 84860337089     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039911     Document Type: Article

References (46)

1. Pack AI, Gislason T. Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 2009; 51: 434-451.
2. Marin JM, Carrizo SJ, Vicente E, et al. Long term cardiovascular outcomes in men with obstructive sleep apnea. Effects of treatment with CPAP. Lancet 2005; 365: 1046-1053.
3. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373: 82-93.
4. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080-1111.
5. Hernandez C, Duran-Cantolla J, Lloberes P, et al. Novedades en la epidemiología, la historia natural,el diagnóstics y el tratamiento del síndrome de apneas-hipopneas durante el sueño [Innovations in the epidemiology, natural history, diagnosis and treatment of sleep apnea-hypopnea syndrome]. Arch Bronconeumol 2009; 45: Suppl. 1, 3-10.
6. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J 1999; 137: S1-S8. (Pubitemid 29162886)
7. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol 1990; 66: 140-144. (Pubitemid 20235718)
8. Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79: 1512-1516. (Pubitemid 27251072)
9. Huikuri HV, Niemela MJ, Ojala S, et al. Circadian rhythms of frequency domain measures of heart rate variability in healthy subjects and patients with coronary artery disease. Effects of arousal and upright posture. Circulation 1994; 90: 121-126. (Pubitemid 24203671)
10. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518. (Pubitemid 17076236)
11. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991; 8: 336-351.
12. Jovicic A, Mandic S. Circadian variations of platelet aggregability and fibrinolytic activity in healthy subjects. Thromb Res 1991; 62: 65-74.
13. Gami AS, Howard DE, Olson EJ, et al. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005; 352: 1206-1214.
14. Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al. Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol 2008; 52: 343-346. (Pubitemid 352001344)
15. Walters J, Skene D, Hampton SM, et al. Biological rhythms, endothelial health and cardiovascular disease. Med Sci Monit 2003; 9: RA1-RA8. (Pubitemid 36206926)
16. Keaney JF Jr, Weaver DR. Vascular rhythms and adaptation: do your arteries know what time it is? Circulation 2009; 119: 1463-1466.
17. Decousus H, Boissier C, Perpoint B, et al. Circadian dynamics of coagulation and chronopathology of cardiovascular and cerebrovascular events. Future therapeutic implications for the treatment of these disorders? Ann NY Acad Sci 1991; 618: 159-165.
18. Kapiotis S, Jilma B, Quehenberger P, et al. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19-21.
19. Pinotti M, Bertolucci C, Portaluppi F, et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005; 25: 646-649. (Pubitemid 40315692)
20. Otto ME, Svatikova A, Barretto RB, et al. Early morning attenuation of endothelial function in healthy humans. Circulation 2004; 109: 2507-2510. (Pubitemid 38720548)
21. Bode-Boger SM, Boger RH, Kielstein JT, et al. Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis. J Investig Med 2000; 48: 125-132.
22. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847. (Pubitemid 28509278)
23. Bridges AB, McLaren M, Scott NA, et al. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J 1993; 69: 121-124. (Pubitemid 23056850)
24. Chrusciel P, Goch A, Banach M, et al. Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med Sci Monit 2009; 15: RA203-RA208.
25. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, et al. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res 2009; 123: 617-621.
26. Aronson D, Weinrauch LA, D'Elia JA, et al. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Am J Cardiol 1999; 84: 449-453. (Pubitemid 29398667)
27. Shaw E, Tofler GH. Circadian rhythm and cardiovascular disease. Curr Atheroscler Rep 2009; 11: 289-295.
28. Rudic RD, Fulton DJ. Pressed for time: the circadian clock and hypertension. J Appl Physiol 2009; 107: 1328-1338.
29. Rana JS, Mukamal KJ, Morgan JP, et al. Circadian variation in the onset of myocardial infarction: effect of duration of diabetes. Diabetes 2003; 52: 1464-1468. (Pubitemid 36666202)
30. von Känel R, Natarajan L, Ancoli-Israel S, et al. Day/night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 2010; 33: 371-377.
31. McLaren G, Hanna C, Mills L, et al. Comparison of sampling methods for obtaining accurate coagulation values in hemodialysis patients with heparinized central venous catheters. Nephrol Nurs J 2001; 28: 632-636.
32. Powers JM. Obtaining blood samples for coagulation studies from a normal saline lock. Am J Crit Care 1999; 8: 250-253.
33. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235. (Pubitemid 20045528)
34. von Känd R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003; 124: 1956-1967.
35. Godsland IF, Crook D, Proudler AJ, et al. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 190-197. (Pubitemid 40116656)
36. Vambergue A, Rugeri L, Gaveriaux V, et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001; 101: 367-375. (Pubitemid 32280847)
37. Reaven GM, Scott EM, Grant PJ, et al. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005; 3: 1074-1085. (Pubitemid 41632841)
38. Unek IT, Bayraktar F, Solmaz D, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res 2010; 8: 89-95.
39. Unek IT, Bayraktar F, Solmaz D, et al. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism 2010; 59: 305-313.
40. Muller JE, Tofler GH, Willich SN, et al. Circadian variation of cardiovascular disease and sympathetic activity. J Cardiovasc Pharmacol 1987; 10: Suppl. 2, S104-S109. (Pubitemid 17160270)
41. Froy O. Metabolism and circadian rhythms - implications for obesity. Endocr Rev 2010; 31: 1-24.
42. Laposky AD, Bass J, Kohsaka A, et al. Sleep and circadian rhythms: key components in the regulation of energy metabolism. FEBS Lett 2008; 582: 142-151. (Pubitemid 350297237)
43. Mehra R, Xu F, Babineau DC, et al. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010; 182: 826-833.
44. Boger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 2003; 4: 1-3. (Pubitemid 38234488)
45. Barcelo A, de la Peña M, Ayllon O, et al. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration 2009; 77: 85-90.
46. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203. (Pubitemid 33043860)